spent in, below and above range (TIR, TBR and TAR, respectively) in people with T1D. A
next generation system, the MiniMed TM AHCL system, that offers a target set point (SP) of
100 or 120mg/dL, autocorrects to 120mg/dL every 5 mins and has fewer Auto Mode exits,
was evaluated. Methods: A 16-site, single-arm, in-home trial of the AHCL system in 39
adolescents (14-21yrs) and 118 adults (≥ 22yrs) with T1D was conducted. After a baseline …